JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
ZacksThe Johnson & Johnson filing seeks the FDA’s approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
The Johnson & Johnson filing seeks the FDA’s approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.